Company: CMND
Filing Date: 2025-12-05
Form Type: F-1/A
Source: 0001213900-25-118772
Chunk: 119

Company: Clearmind Medicine Inc.
Filing Date: 2025-12-05
Form: F-1/A
Chunk 119
---
 inaccurate assumptions and known or unknown risks and uncertainties, including those identified in “Cautionary Note Regarding Forward-Looking Statements” and under “Risk Factors” elsewhere in this prospectus. Our discussion and analysis for the year ended October 31, 2023 can be found in Item 5. “Operating and Financial Review and Prospects” of our Annual Report on Form 20-F for the fiscal year ended October 31, 2023, filed with the SEC on January 29, 2024, as amended by Amendment No. 1 to our Annual Report on Form 20-F for the fiscal year ended October 31, 2023, filed with the SEC on March 18, 2024, as amended by Amendment No. 2 to our Annual Report on Form 20-F for the fiscal year ended October 31, 2023, filed with the SEC on March 27, 2024 (File No. 001-41557). Overview We are a clinical pharmaceutical company currently engaged in phase I/IIa clinical trials of novel psychedelic medicines to solve widespread, yet under-served, health problems. Our goal is to develop and provide new type of treatments for mental health disorders, including AUD, binge drinking and eating disorders, where there is significant unmet need and lack of innovation. We see psychedelic therapies, which previously may have been overlooked or underused, as the future of treatment for a variety of indications. We believe that our solution for AUD can help solve one of the world’s biggest health problems, which costs the United States alone roughly $250 billion each year. We have incurred operating losses each year since our inception, including operating losses of $5,744,925, $6,303,434 and $6,251,431 for the years ended October 31, 2024, 2023 and 2022, respectively, and $4,210,919 and $4,158,744 for the nine months ended July 31, 2025 and 2024, respectively. As of October 31, 2024 and July 31, 2025, we had an accumulated deficit of $24,022,741 and $27,191,882, respectively. We have devoted substantially all of our financial resources to designing and developing MEAI, including preclinical studies and providing general and administrative support for these operations. We expect that our expenses and operating losses will increase for the foreseeable future as we continue clinical development of MEAI for the